Is CRISPR Therapeutics Stock a Buy Now?
An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP). I'm talking about the potential approval of its very first product. The U.S. Food and Drug Administration (FDA) will decide on whether to approve exa-cel for sickle cell disease in December. It offered the company and partner Vertex Pharmaceuticals priority review for that indication.
Meanwhile, CRISPR shares have climbed nearly 40% so far this year. Investors have been closely watching exa-cel development -- and some of the optimism about a possible FDA nod could be baked into today's share price. Does this mean it's too late to get in on this innovative biotech company? Or is CRISPR still a buy now? Let's find out.
So, first a bit of background on exa-cel. It's being developed as a one-time curative treatment for two blood disorders, sickle cell disease and beta thalassemia. Regulators in the U.S., the U.K., and Europe are reviewing the candidate as we speak. The initial approvals would be for adult populations. But the companies continue to conduct phase 3 trials for exa-cel in kids, which could broaden the potential patient population.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Vertex Pharmaceuticals Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Trotz eines Kursziels von 450 €, das unter 468.1 € liegt, ergibt sich für Vertex Pharmaceuticals Inc. ein negatives Potenzial von -3.87%.
